The Vall d’Hebron Institute of Oncology (VHIO) has received 52 grants this year for its research and technical staff that…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
Next Sunday February 4th, coinciding with World Cancer Day, VHIO launches the Cancer 360 podcast, a series of 8 chapters…
On January 25-26, 2024, in Berlin, Germany, the JOIN4ATMP project held its Kick-off meeting, an initiative created to map, join…
“la Caixa” Foundation has subsidized a new transversal platform for next generation single-cell sequencing: UNderstanding cancer through sIngle cell seQUEncing:…
A study led by IRB Barcelona with the collaboration of different VHIO research groups describes a mechanism by which senescent…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
CERTERA’s objective is to create a coordinated research and innovation structure to accelerate the preclinical and early stage clinical development…
Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…
The Vall d’Hebron University Hospital Accredited Health Institute (ISS-IR-HUVH) has been one of those selected for the Fortalece -Salud program…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
Led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Experimental Hematology Group and the Advanced Therapies Program of…
